|
1
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Botter SM, Neri D and Fuchs B: Recent
advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin PP and Patel S: OsteosarcomaBone
sarcoma. Springer; New York, NY: pp. 75–97. 2013, View Article : Google Scholar
|
|
5
|
Tsukahara T and Wada T: Immunotherapy for
osteosarcomaOsteosarcoma. Springer; Tokyo: pp. 31–41. 2016,
View Article : Google Scholar
|
|
6
|
Farfalli GL, Albergo JI, Lobos PA, Smith
DE, Streitenberger PD, Pallotta Rodríguez MG and Aponte-Tinao LA:
Osteosarcoma lung metastases. Survival after chemotherapy and
surgery. Medicina (B Aires). 75:87–90. 2015.(In Spanish).
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zimmerman AL and Wu S: MicroRNAs, cancer
and cancer stem cells. Cancer Lett. 300:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor. Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou X, Ren Y, Moore L, Mei M, You Y, Xu
P, Wang B, Wang G, Jia Z, Pu P, et al: Downregulation of miR-21
inhibits EGFR pathway and suppresses the growth of human
glioblastoma cells independent of PTEN status. Lab Invest.
90:144–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li S, Fan Q, He S, Tang T, Liao Y and Xie
J: MicroRNA-21 negatively regulates Treg cells through a
TGF-β1/Smad-independent pathway in patients with coronary heart
disease. Cell Physiol Biochem. 37:866–878. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Xie W, Xie C, Huang C, Zhu J, Liang
Z, Deng F, Zhu M, Zhu W, Wu R, et al: Curcumin modulates
miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7
breast cancer cell proliferation. Phytother Res. 28:1553–1560.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Ballim D, Rodriguez M, Cui R, Goding
CR, Teng H and Prince S: The anti-proliferative function of the
TGF-β1 signaling pathway involves the repression of the oncogenic
TBX2 by its homologue TBX3. J Biol Chem. 289:35633–35643. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duan Z, Choy E, Harmon D, Liu X, Susa M,
Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human
osteosarcoma and regulates cell proliferation and migration. Mol
Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin J, Cai L, Liu ZM and Zhou XS:
miRNA-218 inhibits osteosarcoma cell migration and invasion by
down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev.
14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou Y, Huang Z, Wu S, Zang X, Liu M and
Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and
promotes osteosarcoma cell resistance to cisplatin by
down-regulating TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vanas V, Haigl B, Stockhammer V and
Sutterlüty-Fall H: MicroRNA-21 increases proliferation and
cisplatin sensitivity of osteosarcoma-derived cells. PLoS One.
11:e01610232016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang H, Xie J, Zhang M, Zhao Z, Wan Y and
Yao Y: miRNA-21 promotes proliferation and invasion of
triple-negative breast cancer cells through targeting PTEN. Am J
Transl Res. 9:953–961. 2017.PubMed/NCBI
|
|
22
|
Jacobson S, Kechris K, Sun W, Yang J, Chen
TH, Barr RG, Basta P, Bleecker ER, Couper D, Curtis JF, et al:
Blood biomarker quantitative trail loci in chronic obstructive
pulmonary disease. B93. Genetic signatures of Asthma: Key to
endotypes? Am Thorac Soc. 191:A36272015.
|
|
23
|
Han Y, Xu GX, Lu H, Yu DH, Ren Y, Wang L,
Huang XH, Hou WJ, Wei ZH, Chen YP, et al: Dysregulation of miRNA-21
and their potential as biomarkers for the diagnosis of cervical
cancer. Int J Clin Exp Pathol. 8:7131–7139. 2015.PubMed/NCBI
|
|
24
|
Shi R, Wang PY, Li XY, Chen JX, Li Y,
Zhang XZ, Zhang CG, Jiang T, Li WB, Ding W and Cheng SJ: Exosomal
levels of miRNA-21 from cerebrospinal fluids associated with poor
prognosis and tumor recurrence of glioma patients. Oncotarget.
6:26971–26981. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan J, Chen L, Chen X, Sun W and Zhou X:
Identification of serum microRNA-21 as a biomarker for
chemosensitivity and prognosis in human osteosarcoma. J Int Med
Res. 40:2090–2097. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ziyan W, Shuhua Y, Xiufang W and Xiaoyun
L: MicroRNA-21 is involved in osteosarcoma cell invasion and
migration. Med Oncol. 28:1469–1474. 2011. View Article : Google Scholar : PubMed/NCBI
|
